1
|
Tannoury M, Ayoub M, Dehgane L, Nemazanyy I, Dubois K, Izabelle C, Brousse A, Roos-Weil D, Maloum K, Merle-Béral H, Bauvois B, Saubamea B, Chapiro E, Nguyen-Khac F, Garnier D, Susin SA. ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia. Leukemia 2024; 38:302-317. [PMID: 38057495 DOI: 10.1038/s41375-023-02103-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 11/17/2023] [Accepted: 11/24/2023] [Indexed: 12/08/2023]
Abstract
Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients developing resistance to conventional and targeted therapies. To better understand the physiology of CLL and facilitate the development of innovative treatment options, we examined specific metabolic features in the tumor CLL B-lymphocytes. We observed metabolic reprogramming, characterized by a high level of mitochondrial oxidative phosphorylation activity, a low glycolytic rate, and the presence of C2- to C6-carnitine end-products revealing an unexpected, essential role for peroxisomal fatty acid beta-oxidation (pFAO). Accordingly, downmodulation of ACOX1 (a rate-limiting pFAO enzyme overexpressed in CLL cells) was enough to shift the CLL cells' metabolism from lipids to a carbon- and amino-acid-based phenotype. Complete blockade of ACOX1 resulted in lipid droplet accumulation and caspase-dependent death in CLL cells, including those from individuals with poor cytogenetic and clinical prognostic factors. In a therapeutic translational approach, ACOX1 inhibition spared non-tumor blood cells from CLL patients but led to the death of circulating, BCR-stimulated CLL B-lymphocytes and CLL B-cells receiving pro-survival stromal signals. Furthermore, a combination of ACOX1 and BTK inhibitors had a synergistic killing effect. Overall, our results highlight a less-studied but essential metabolic pathway in CLL and pave the way towards the development of new, metabolism-based treatment options.
Collapse
Affiliation(s)
- Mariana Tannoury
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Marianne Ayoub
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Léa Dehgane
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Ivan Nemazanyy
- Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR 3633, Platform for Metabolic Analyses, F-75015, Paris, France
| | - Kenza Dubois
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Charlotte Izabelle
- Faculté de Pharmacie, Université Paris Cité, PICMO, US 25 Inserm, UAR 3612 CNRS, F-75006, Paris, France
| | - Aurélie Brousse
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Damien Roos-Weil
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
- Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Clinique, F-75013, Paris, France
| | - Karim Maloum
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
- Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, F-75013, Paris, France
| | - Hélène Merle-Béral
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Brigitte Bauvois
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Bruno Saubamea
- Faculté de Pharmacie, Université Paris Cité, PICMO, US 25 Inserm, UAR 3612 CNRS, F-75006, Paris, France
| | - Elise Chapiro
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
- Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, F-75013, Paris, France
| | - Florence Nguyen-Khac
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
- Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, F-75013, Paris, France
| | - Delphine Garnier
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France
| | - Santos A Susin
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006, Paris, France.
| |
Collapse
|
2
|
Bauvois B, Chapiro E, Quiney C, Maloum K, Susin SA, Nguyen-Khac F. The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target? Biomedicines 2023; 11:2335. [PMID: 37760777 PMCID: PMC10525793 DOI: 10.3390/biomedicines11092335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 08/14/2023] [Accepted: 08/18/2023] [Indexed: 09/29/2023] Open
Abstract
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes that escape death, and correlates with the expression of negative prognostic markers such as the CD38 antigen. Although certain new drugs approved by the US Food and Drug Administration improve the clinical outcome of CLL patients, drug resistance and disease relapse still occur. Like CD38, neutrophil gelatinase-associated lipocalin receptor (NGAL-R) is frequently overexpressed in CLL cells. Here, we evaluated the concomitant surface expression of NGAL-R and CD38 in leukemic blood cells from 52 CLL patients (37 untreated, 8 in clinical remission, and 7 relapsed). We provide evidence of a positive correlation between NGAL-R and CD38 levels both in the interpatient cohorts (p < 0.0001) and in individual patients, indicating a constitutive association of NGAL-R and CD38 at the cell level. Patients with progressing CLL showed a time-dependent increase in NGAL-R/CD38 levels. In treated CLL patients who achieved clinical remission, NGAL-R/CD38 levels were decreased, and were significantly lower than in the untreated and relapsed groups (p < 0.02). As NGAL-R and CD38 participate in CLL cell survival, envisioning their simultaneous inhibition with bispecific NGAL-R/CD38 antibodies capable of inducing leukemic cell death might provide therapeutic benefit for CLL patients.
Collapse
Affiliation(s)
- Brigitte Bauvois
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France; (E.C.); (K.M.); (S.A.S.); (F.N.-K.)
| | - Elise Chapiro
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France; (E.C.); (K.M.); (S.A.S.); (F.N.-K.)
- Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d’Hématologie Biologique, F-75013 Paris, France;
| | - Claire Quiney
- Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d’Hématologie Biologique, F-75013 Paris, France;
| | - Karim Maloum
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France; (E.C.); (K.M.); (S.A.S.); (F.N.-K.)
- Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d’Hématologie Biologique, F-75013 Paris, France;
| | - Santos A. Susin
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France; (E.C.); (K.M.); (S.A.S.); (F.N.-K.)
| | - Florence Nguyen-Khac
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France; (E.C.); (K.M.); (S.A.S.); (F.N.-K.)
- Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Service d’Hématologie Biologique, F-75013 Paris, France;
| |
Collapse
|
3
|
Dubois K, Tannoury M, Bauvois B, Susin SA, Garnier D. Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies? Cancers (Basel) 2023; 15:cancers15082307. [PMID: 37190234 DOI: 10.3390/cancers15082307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/07/2023] [Accepted: 04/12/2023] [Indexed: 05/17/2023] Open
Abstract
In addition to intrinsic genomic and nongenomic alterations, tumor progression is also dependent on the tumor microenvironment (TME, mainly composed of the extracellular matrix (ECM), secreted factors, and bystander immune and stromal cells). In chronic lymphocytic leukemia (CLL), B cells have a defect in cell death; contact with the TME in secondary lymphoid organs dramatically increases the B cells' survival via the activation of various molecular pathways, including the B cell receptor and CD40 signaling. Conversely, CLL cells increase the permissiveness of the TME by inducing changes in the ECM, secreted factors, and bystander cells. Recently, the extracellular vesicles (EVs) released into the TME have emerged as key arbiters of cross-talk with tumor cells. The EVs' cargo can contain various bioactive substances (including metabolites, proteins, RNA, and DNA); upon delivery to target cells, these substances can induce intracellular signaling and drive tumor progression. Here, we review recent research on the biology of EVs in CLL. EVs have diagnostic/prognostic significance and clearly influence the clinical outcome of CLL; hence, from the perspective of blocking CLL-TME interactions, EVs are therapeutic targets. The identification of novel EV inhibitors might pave the way to the development of novel combination treatments for CLL and the optimization of currently available treatments (including immunotherapy).
Collapse
Affiliation(s)
- Kenza Dubois
- Sorbonne Université, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| | - Mariana Tannoury
- Sorbonne Université, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| | - Brigitte Bauvois
- Sorbonne Université, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| | - Santos A Susin
- Sorbonne Université, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| | - Delphine Garnier
- Sorbonne Université, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| |
Collapse
|
4
|
Tannoury M, Garnier D, Susin SA, Bauvois B. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? Cancers (Basel) 2022; 14:6026. [PMID: 36551511 PMCID: PMC9775488 DOI: 10.3390/cancers14246026] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 11/29/2022] [Accepted: 12/03/2022] [Indexed: 12/13/2022] Open
Abstract
Resistance to death is one of the hallmarks of human B cell malignancies and often contributes to the lack of a lasting response to today's commonly used treatments. Drug discovery approaches designed to activate the death machinery have generated a large number of inhibitors of anti-apoptotic proteins from the B-cell lymphoma/leukemia 2 family and the B-cell receptor (BCR) signaling pathway. Orally administered small-molecule inhibitors of Bcl-2 protein and BCR partners (e.g., Bruton's tyrosine kinase and phosphatidylinositol-3 kinase) have already been included (as monotherapies or combination therapies) in the standard of care for selected B cell malignancies. Agonistic monoclonal antibodies and their derivatives (antibody-drug conjugates, antibody-radioisotope conjugates, bispecific T cell engagers, and chimeric antigen receptor-modified T cells) targeting tumor-associated antigens (TAAs, such as CD19, CD20, CD22, and CD38) are indicated for treatment (as monotherapies or combination therapies) of patients with B cell tumors. However, given that some patients are either refractory to current therapies or relapse after treatment, novel therapeutic strategies are needed. Here, we review current strategies for managing B cell malignancies, with a focus on the ongoing clinical development of more effective, selective drugs targeting these molecules, as well as other TAAs and signaling proteins. The observed impact of metabolic reprogramming on B cell pathophysiology highlights the promise of targeting metabolic checkpoints in the treatment of these disorders.
Collapse
Affiliation(s)
| | | | | | - Brigitte Bauvois
- Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France
| |
Collapse
|
5
|
Ben Arfa A, Boulaaba M, Merhi F, Bauvois B, Ingrid A, Auger J, Neffati M, Najjaa H. Effects of
Allium roseum
L. extracts on the proliferation and the differentiation of the acute myeloid leukemia cell line
U937. Food Sci Nutr 2022; 11:2099-2105. [PMID: 37181314 PMCID: PMC10171498 DOI: 10.1002/fsn3.2965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/23/2022] [Accepted: 06/17/2022] [Indexed: 11/11/2022] Open
Abstract
Epidemiologic studies keep up the proposition that Allium vegetables can lower the risk of cancers. Acute myeloid leukemia (AML) cells exhibit high proliferative potency and have a reduced capacity of undergoing apoptosis and maturation. The beneficial effects of Allium seem related to the organosulfur products generated upon processing of these species. For this purpose, the aim of this study was to test Allium roseum fresh (FAE), crude (CAE) and dried (DAE) aqueous extracts for activity against the human acute leukemia cell line (U937). As assessed by flow cytometry, inhibited cell proliferation was in a dose-dependent manner. Firstly, study showed that cell growth was inhibited with 20 mg/mL using FAE and CAE (60% and 73% respectively). Secondly, our experiments clearly indicate that all A. roseum extracts do not induce cell apoptosis. This was confirmed by the soft binding of Annexin V to phosphatidylserine. Finally, the high expression of macrophage's marker CD11 associated with adequate morphological changes proves clearly the differentiation aspect produced by A. roseum extract. Taken together, these data suggest that A. roseum could be a promising candidate for the alternative medicine in the field of cancer therapy.
Collapse
Affiliation(s)
- Abdelkarim Ben Arfa
- Laboratoire des Ecosystèmes Pastoraux et de Valorization des Plantes Spontanées Institut des Régions Arides Université de Gabès Médenine Tunisie
| | - Mondher Boulaaba
- Laboratoire des Plantes Aromatiques et Médicinales, Centre de Biotechnologie Technopark de Borj‐Cédria (CBBC) Hammam‐Lif Tunisie
| | - Faten Merhi
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes Centre de Recherche des Cordeliers Paris France
| | - Brigitte Bauvois
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes Centre de Recherche des Cordeliers Paris France
| | - Arnault Ingrid
- IRBI, UMR CNRS 6035 Université François Rabelais Tours France
| | - Jacques Auger
- IRBI, UMR CNRS 6035 Université François Rabelais Tours France
| | - Mohamed Neffati
- Laboratoire des Ecosystèmes Pastoraux et de Valorization des Plantes Spontanées Institut des Régions Arides Université de Gabès Médenine Tunisie
| | - Hanen Najjaa
- Laboratoire des Ecosystèmes Pastoraux et de Valorization des Plantes Spontanées Institut des Régions Arides Université de Gabès Médenine Tunisie
| |
Collapse
|
6
|
Verhulst E, Garnier D, De Meester I, Bauvois B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers (Basel) 2022; 14:cancers14030624. [PMID: 35158891 PMCID: PMC8833564 DOI: 10.3390/cancers14030624] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 01/20/2022] [Accepted: 01/21/2022] [Indexed: 02/06/2023] Open
Abstract
Simple Summary Cell surface proteases (so-called ectoproteases) are associated with cancer, and their targeting may confer valuable options for the improvement of cancer treatment outcome. Over the past 20 years, the permanent development of a multitude of inhibitors against several ectoproteases (including DPP4, FAP, APN, ADAM17, MMP2, and MMP9) has made it into clinical evaluation in haematological and solid tumours. Among them, a few show some efficacy, albeit limited, to cure cancer in the near future. This Review summarizes the efforts thus far undertaken in the development of ectoprotease inhibitors and highlights new directions for targeting ectoproteases as an additional weapon in the fight against cancer. Abstract Cell surface proteases (also known as ectoproteases) are transmembrane and membrane-bound enzymes involved in various physiological and pathological processes. Several members, most notably dipeptidyl peptidase 4 (DPP4/CD26) and its related family member fibroblast activation protein (FAP), aminopeptidase N (APN/CD13), a disintegrin and metalloprotease 17 (ADAM17/TACE), and matrix metalloproteinases (MMPs) MMP2 and MMP9, are often overexpressed in cancers and have been associated with tumour dysfunction. With multifaceted actions, these ectoproteases have been validated as therapeutic targets for cancer. Numerous inhibitors have been developed to target these enzymes, attempting to control their enzymatic activity. Even though clinical trials with these compounds did not show the expected results in most cases, the field of ectoprotease inhibitors is growing. This review summarizes the current knowledge on this subject and highlights the recent development of more effective and selective drugs targeting ectoproteases among which small molecular weight inhibitors, peptide conjugates, prodrugs, or monoclonal antibodies (mAbs) and derivatives. These promising avenues have the potential to deliver novel therapeutic strategies in the treatment of cancers.
Collapse
Affiliation(s)
- Emile Verhulst
- Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2000 Antwerp, Belgium; (E.V.); (I.D.M.)
| | - Delphine Garnier
- Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France;
| | - Ingrid De Meester
- Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2000 Antwerp, Belgium; (E.V.); (I.D.M.)
| | - Brigitte Bauvois
- Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France;
- Correspondence:
| |
Collapse
|
7
|
Bauvois B, Susin SA. Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner? Cancers (Basel) 2018; 10:cancers10090336. [PMID: 30231474 PMCID: PMC6162539 DOI: 10.3390/cancers10090336] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 09/13/2018] [Accepted: 09/15/2018] [Indexed: 12/13/2022] Open
Abstract
Human neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein present in a wide variety of tissues and cell types. NGAL exists as a 25 kDa monomer, a 46 kDa homodimer (the most abundant form in healthy subjects) and a 130 kDa disulfide-linked heterodimer bound to latent matrix metalloproteinase-9. Dysregulated expression of NGAL in human malignancies suggests its value as a clinical marker. A growing body of evidence is highlighting NGAL’s paradoxical (i.e., both beneficial and detrimental) effects on cellular processes associated with tumor development (proliferation, survival, migration, invasion, and multidrug resistance). At least two distinct cell surface receptors are identified for NGAL. This review (i) summarizes our current knowledge of NGAL’s expression profiles in solid tumors and leukemias, and (ii) critically evaluates the beneficial and detrimental activities of NGAL having been documented in a diverse range of cancer-derived cell lines. A better understanding of the causal relationships between NGAL dysregulation and tumor development will require a fine analysis of the molecular aspects and biological role(s) of NGAL both in primary tumors and at different stages of disease. Having an accurate picture of NGAL’s contribution to tumor progression is a prerequisite for attempting to modulate this protein as a putative therapeutic target.
Collapse
Affiliation(s)
- Brigitte Bauvois
- INSERM UMRS 1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, 75006 Paris, France.
- Sorbonne Universités Paris Cité, F-75006 Paris, France.
- Université Paris Descartes, F-75005 Paris, France.
| | - Santos A Susin
- INSERM UMRS 1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, 75006 Paris, France.
- Sorbonne Universités Paris Cité, F-75006 Paris, France.
- Université Paris Descartes, F-75005 Paris, France.
| |
Collapse
|
8
|
Bouchet S, Tang R, Fava F, Legrand O, Bauvois B. The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13. Oncotarget 2017; 7:19445-67. [PMID: 26655501 PMCID: PMC4991394 DOI: 10.18632/oncotarget.6523] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 11/16/2015] [Indexed: 02/06/2023] Open
Abstract
The CD13 antigen's binding site for the Asn-Gly-Arg (NGR) motif enables NGR-containing chemotherapeutic drugs to be delivered to CD13-positive tumours. Human CD13-positive acute myeloid leukemia (AML) cells proliferate abnormally and escape death. Here, we show that the CNGRC-GG-D(KLAKLAK)2 peptide induces death in AML cell lines (U937, THP-1, NB4, HL-60) and primary blood cells from AML patients. Cell death was characterized as a caspase-independent mechanism, without DNA fragmentation, but phosphatidylserine externalization and membrane disruption. Our results demonstrate in U937 cells that (i) the NGR-peptide triggers the loss of mitochondrial potential(ΔΨm) and generates superoxide anion (O2-), (ii) N-acetyl-L-cysteine (NAC) and extra/intracellular Ca2+ chelators (BAPTA) prevent both O2- production and cell death, (iii) the Ca2+-channel blocker nifedipine prevents cell death (indicating that Ca2+ influx is the initial death trigger), and (iv) BAPTA, but not NAC, prevents ΔΨm loss (suggesting O2- is a mitochondrial downstream effector). AML cell lines and primary blasts responding to the lethal action of NGR-peptide express promatrix metalloproteinase-12 (proMMP-12) and its substrate progranulin (an 88 kDa cell survival factor). A cell-free assay highlighted proMMP-12 activation by O2-. Accordingly, NGR-peptide's downregulation of 88 kDa progranulin protein was prevented by BAPTA and NAC. Conversely, AML blast resistance to NGR-peptide is associated with the expression of a distinct, 105 kDa progranulin isoform. These results indicate that CNGRC-GG-D(KLAKLAK)2 induces death in AML cells through the Ca2+-mitochondria-O2.-pathway, and support the link between proMMP-12 activation and progranulin cleavage during cell death. Our findings may have implications for the understanding of tumour biology and treatment.
Collapse
Affiliation(s)
- Sandrine Bouchet
- Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France.,Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Ruoping Tang
- Centre de Recherche de Saint-Antoine, INSERM UMRS 938, Service d'Hématologie, Hôpital St Antoine, Paris, France.,Sorbonne Universités UPMC Paris 06, Paris, France
| | - Fanny Fava
- Centre de Recherche de Saint-Antoine, INSERM UMRS 938, Service d'Hématologie, Hôpital St Antoine, Paris, France.,Sorbonne Universités UPMC Paris 06, Paris, France
| | - Ollivier Legrand
- Centre de Recherche de Saint-Antoine, INSERM UMRS 938, Service d'Hématologie, Hôpital St Antoine, Paris, France.,Sorbonne Universités UPMC Paris 06, Paris, France
| | - Brigitte Bauvois
- Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| |
Collapse
|
9
|
Bchir S, Nasr HB, Bouchet S, Benzarti M, Garrouch A, Tabka Z, Susin S, Chahed K, Bauvois B. Concomitant elevations of MMP-9, NGAL, proMMP-9/NGAL and neutrophil elastase in serum of smokers with chronic obstructive pulmonary disease. J Cell Mol Med 2016; 21:1280-1291. [PMID: 28004483 PMCID: PMC5487915 DOI: 10.1111/jcmm.13057] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 11/10/2016] [Indexed: 12/22/2022] Open
Abstract
A growing body of evidence points towards smoking‐related phenotypic differences in chronic obstructive pulmonary disease (COPD). As COPD is associated with systemic inflammation, we determined whether smoking status is related to serum levels of matrix metalloproteinase‐9 (pro‐ and active MMP‐9), neutrophil gelatinase‐associated lipocalin (NGAL) and the proMMP‐9/NGAL complex in patients with COPD. Serum samples were collected in 100 stable‐phase COPD patients (82 smokers, 18 never‐smokers) and 28 healthy adults (21 smokers, 7 never‐smokers). Serum levels of studied factors were measured in ELISA. Our data provide the first evidence of simultaneously elevated serum levels of MMP‐9, NGAL and proMMP‐9/NGAL in COPD smokers. While the triad discriminated between smokers and non‐smokers in the COPD group, MMP‐9 and proMMP‐9/NGAL (but not NGAL) discriminated between smokers with and without COPD. Adjustment for age and smoking pack‐years did not alter the findings. Serum MMP‐9, NGAL and proMMP‐9/NGAL levels were not correlated with the GOLD stage or FEV1 decline. Furthermore, serum levels of neutrophil elastase (NE) and MMP‐3 (but not of IL‐6 and MMP‐12) were also higher in COPD smokers than in healthy smokers before and after adjustment for age and pack‐years. Among COPD smokers, levels of MMP‐9, NGAL and proMMP‐9/NGAL were positively correlated with NE (P < 0.0001) but not with the remaining factors. Gelatin zymography detected proMMP‐9 in serum samples of healthy and COPD smoking groups. Our results suggest that associated serum levels of proMMP‐9, NGAL, proMMP‐9/NGAL and NE may reflect the state of systemic inflammation in COPD related to cigarette smoking.
Collapse
Affiliation(s)
- Sarra Bchir
- Unité de recherche UR12ES06, Physiologie de l'Exercice et Physiopathologie de l'Intégré au Moléculaire, Biologie, Médecine et Santé, Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.,Institut Supérieur de Biotechnologie de Monastir, Université de Monastir, Monastir, Tunisia.,Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Hela Ben Nasr
- Unité de recherche UR12ES06, Physiologie de l'Exercice et Physiopathologie de l'Intégré au Moléculaire, Biologie, Médecine et Santé, Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia
| | - Sandrine Bouchet
- Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France.,Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Mohamed Benzarti
- Service de Pneumo-Allergologie, CHU Farhat Hached, Sousse, Tunisia
| | | | - Zouhair Tabka
- Unité de recherche UR12ES06, Physiologie de l'Exercice et Physiopathologie de l'Intégré au Moléculaire, Biologie, Médecine et Santé, Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia
| | - Santos Susin
- Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Karim Chahed
- Unité de recherche UR12ES06, Physiologie de l'Exercice et Physiopathologie de l'Intégré au Moléculaire, Biologie, Médecine et Santé, Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.,Faculté des Sciences de Sfax, Université de Sfax, Sfax, Tunisia
| | - Brigitte Bauvois
- Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| |
Collapse
|
10
|
Bouchet S, Dauzonne D, Bauvois B, Piedfer M, Susin S. In vitro activity of some flavonoid derivatives on human leukemic myeloid cells: evidence for aminopeptidase-N (CD13) inhibition, antiproliferative and cell death properties. AIMS Molecular Science 2016. [DOI: 10.3934/molsci.2016.3.368] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
11
|
Liu Y, Aron-Wisnewsky J, Marcelin G, Genser L, Le Naour G, Torcivia A, Bauvois B, Bouchet S, Pelloux V, Sasso M, Miette V, Tordjman J, Clément K. Accumulation and Changes in Composition of Collagens in Subcutaneous Adipose Tissue After Bariatric Surgery. J Clin Endocrinol Metab 2016; 101:293-304. [PMID: 26583585 DOI: 10.1210/jc.2015-3348] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Extracellular matrix (ECM) in sc adipose tissue (scAT) undergoes pathological remodeling during obesity. However, its evolution during weight loss remains poorly explored. OBJECTIVE The objective of the investigation was to study the histological, transcriptomic, and physical characteristics of scAT ECM remodeling during the first year of bariatric surgery (BS)-induced weight loss and their relationships with metabolic and bioclinical improvements. DESIGN, SETTING, PATIENTS, AND INTERVENTIONS A total of 118 morbidly obese candidates for BS were recruited and followed up during 1 year after BS. MAIN OUTCOME MEASURES scAT surgical biopsy and needle aspiration as well as scAT stiffness measurement were performed in three subgroups before and after BS. Fourteen nonobese, nondiabetic subjects served as controls. RESULTS Significantly increased picrosirius-red-stained collagen accumulation in scAT after BS was observed along with fat mass loss, despite metabolic and inflammatory improvements and undetectable changes of scAT stiffness. Collagen accumulation positively associated with M2-macrophages (CD163(+) cells) before BS but negatively afterward. Expression levels of genes encoding ECM components (eg, COL3A1, COL6A1, COL6A2, ELN), cross-linking enzymes (eg, lysyl oxidase [LOX], LOXL4, transglutaminase), metalloproteinases, and their inhibitors were modified 1 year after BS. LOX expression and protein were significantly decreased and associated with decreased fat mass as well as other cross-linking enzymes. Although total collagen I and VI staining decreased 1 year after BS, we found increased degraded collagen I and III in scAT, suggesting increased degradation. CONCLUSIONS After BS-induced weight loss and related metabolic improvements, scAT displays major collagen remodeling with an increased picrosirius-red staining that relates to increased collagen degradation and importantly decreased cross-linking. These features are in agreement with adequate ECM adaptation during fat mass loss.
Collapse
Affiliation(s)
- Yuejun Liu
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Judith Aron-Wisnewsky
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Geneviève Marcelin
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Laurent Genser
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Gilles Le Naour
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Adriana Torcivia
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Brigitte Bauvois
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Sandrine Bouchet
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Véronique Pelloux
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Magali Sasso
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Véronique Miette
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Joan Tordjman
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| | - Karine Clément
- Institute of Cardiometabolism and Nutrition (ICAN) (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), INSERM (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Unité Mixte de Recherche en Santé 1166, Nutriomic Team 6; Departments of Nutrition (J.A.-W., K.C.) and Digestive and Hepato-Pancreato-Biliary Surgery (L.G., A.T.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Department of Pathology (G.L.N.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité d'Imagerie Numérique Morphologique en Anatomo-Pathologie, Université Pierre et Marie Curie, F-75013 Paris, France; Unité Mixte de Recherche en Santé 1166 (Y.L., J.A.-W., G.M., L.G., V.P., J.T., K.C.), Sorbonne Universités, Université Pierre et Marie Curie Paris 06, F-75005, Paris, France; Research Department of Echosens company (Y.L., M.S., V.M.), 75013, Paris, France; Centre de Recherche des Cordeliers (B.B., S.B.), INSERM Unité Mixte de Recherche en Santé 1138, Sorbonne Universités, Université Pierre et Marie Curie, and Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
| |
Collapse
|
12
|
Bchir S, Nasr HB, Hakim IR, Anes AB, Yacoub S, Garrouch A, Benzarti M, Bauvois B, Tabka Z, Chahed K. Matrix Metalloproteinase-9 (279R/Q) Polymorphism is Associated with Clinical Severity and Airflow Limitation in Tunisian Patients with Chronic Obstructive Pulmonary Disease. Mol Diagn Ther 2015; 19:375-87. [DOI: 10.1007/s40291-015-0163-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
13
|
Affiliation(s)
- Brigitte Bauvois
- Institut National de la Santé et de la Recherche Médicale, UMRS1138, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris Descartes, Paris, France
| |
Collapse
|
14
|
Bouchet S, Bauvois B. Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias. Cancers (Basel) 2014; 6:796-812. [PMID: 24713998 PMCID: PMC4074804 DOI: 10.3390/cancers6020796] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2013] [Revised: 03/21/2014] [Accepted: 03/25/2014] [Indexed: 12/22/2022] Open
Abstract
Matrix metalloproteinase (MMP)-9 and neutrophil gelatinase-associated lipocalin (NGAL) have gained attention as cancer biomarkers. The inactive zymogen form of MMP-9 (pro-MMP-9) also exists as a disulphide-linked heterodimer bound to NGAL in humans. Leukaemias represent a heterogeneous group of neoplasms, which vary in their clinical behavior and pathophysiology. In this review, we summarize the current literature on the expression profiles of pro-MMP-9 and NGAL as prognostic factors in leukaemias. We also report the expression of the pro-MMP-9/NGAL complex in these diseases. We discuss the roles of (pro)-MMP-9 (active and latent forms) and NGAL in tumour development, and evaluate the mechanisms by which pro-MMP-9/NGAL may influence the actions of (pro)-MMP-9 and NGAL in cancer. Emerging knowledge about the coexpression and the biology of (pro)-MMP-9, NGAL and their complex in cancer including leukaemia may improve treatment outcomes.
Collapse
Affiliation(s)
- Sandrine Bouchet
- INSERM U1138, Université Pierre et Marie Curie, Université Paris-Descartes, Centre de Recherche des Cordeliers, Paris 75006, France.
| | - Brigitte Bauvois
- INSERM U1138, Université Pierre et Marie Curie, Université Paris-Descartes, Centre de Recherche des Cordeliers, Paris 75006, France.
| |
Collapse
|
15
|
Piedfer M, Bouchet S, Tang R, Billard C, Dauzonne D, Bauvois B. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. Biochim Biophys Acta 2013; 1833:1316-28. [PMID: 23481040 DOI: 10.1016/j.bbamcr.2013.02.016] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2012] [Revised: 01/17/2013] [Accepted: 02/15/2013] [Indexed: 12/01/2022]
Abstract
Acute myeloid leukemia (AML) is a deadly disease characterized by the clonal expansion and accumulation of hematopoietic stem cells arrested at various stages of development. Clinical research efforts are currently focusing on targeted therapies that induce apoptosis in AML cells. Herein, the effects and mechanisms of the novel flavone 3,3'-diamino-4'-methoxyflavone (DD1) on AML cell dysfunction were investigated in AML cells (monoblast U937, myelomonocyte OCI-AML3, promyelocyte NB4, myeloblast HL-60) and blood samples from patients with AML. The administration of DD1 inhibited proliferation and induced death of AML cell lines and reduced the clonogenic activity of AML, but not normal, blood cells. The flavone's apoptotic action in U937 cells was associated with recruitment of mitochondria, Bax activation, Bad dephosphorylation (at Ser(136)), activation of caspases -8, -9, and -3 and cleavage of the caspase substrate PARP-1. DD1 induced a marked decrease in (i) Thr(389)-phosphorylation and (ii) protein levels of the caspase-3 substrate P70 ribosomal S6 kinase (P70S6K, known for its ability to phosphorylate Bad). Caspase-dependent apoptosis and P70S6K degradation were simultaneously prevented by the caspase inhibitors. Importantly, DD1 was shown to directly inhibit the proteasome's chymotrypsin-like activity in U937 cells. Apoptotic activity of the proteasome inhibitor bortezomib was also related to Bax activation and P70S6K downregulation. Accordingly, DD1 failed to induce P70S6K cleavage, Bax stimulation and apoptosis in K562 cells resistant to bortezomib. These results indicate that DD1 has the potential to eradicate AML cells and support a critical role for Bax and P70S6K in DD1-mediated proteasome inhibition and apoptosis of leukemia cells.
Collapse
Affiliation(s)
- Marion Piedfer
- Université Pierre et Marie Curie, Université Paris-Descartes, Centre de Recherche des Cordeliers, Paris, France
| | | | | | | | | | | |
Collapse
|
16
|
|
17
|
|
18
|
Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. Curr Cancer Drug Targets 2013; 13:1-10. [PMID: 22924417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Revised: 06/12/2012] [Accepted: 08/01/2012] [Indexed: 06/01/2023]
Abstract
Hyperforin is a prenylated phloroglucinol present in the medicinal plant St John's wort (Hypericum perforatum). The compound has many biological properties, including antidepressant, anti-inflammatory, antibacterial and antitumor activities. This review focuses on the in vitro antileukemic effects of purified hyperforin and related mechanisms in chronic lymphoid leukemia (CLL) and acute myeloid leukemia (AML) - conditions that are known for their resistance to chemotherapy. Hyperforin induces apoptosis in both CLL and AML cells. In AML cell lines and primary AML cells, hyperforin directly inhibits the kinase activity of the serine/threonine protein kinase B/AKT1, leading to activation of the pro-apoptotic Bcl-2 family protein Bad through its non-phosphorylation by AKT1. In primary CLL cells, hyperforin acts by stimulating the expression of the pro-apoptotic Bcl-2 family member Noxa (possibly through the inhibition of proteasome activity). Other hyperforin targets include matrix metalloproteinase-2 in AML cells and vascular endothelial growth factor and matrix metalloproteinase-9 in CLL cells - two mediators of cell migration and angiogenesis. In summary, hyperforin targets molecules involved in signaling pathways that control leukemic cell proliferation, survival, apoptosis, migration and angiogenesis. Hyperforin also downregulates the expression of P-glycoprotein, a protein that is involved in the resistance of leukemia cells to chemotherapeutic agents. Lastly, native hyperforin and its stable derivatives show interesting in vivo properties in animal models. In view of their low toxicity, hyperforin and its derivatives are promising antileukemic agents and deserve further investigation in vivo.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- Animals
- Antineoplastic Agents, Phytogenic/adverse effects
- Antineoplastic Agents, Phytogenic/pharmacology
- Antineoplastic Agents, Phytogenic/therapeutic use
- Apoptosis/drug effects
- Drug Resistance, Neoplasm/drug effects
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/enzymology
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/enzymology
- Leukemia, Myeloid, Acute/metabolism
- Leukocytes/drug effects
- Leukocytes/enzymology
- Leukocytes/metabolism
- Neoplasm Proteins/antagonists & inhibitors
- Phloroglucinol/adverse effects
- Phloroglucinol/analogs & derivatives
- Phloroglucinol/pharmacology
- Phloroglucinol/therapeutic use
- Proteasome Endopeptidase Complex/drug effects
- Proteasome Endopeptidase Complex/metabolism
- Protein Kinase Inhibitors/adverse effects
- Protein Kinase Inhibitors/pharmacology
- Protein Kinase Inhibitors/therapeutic use
- Proto-Oncogene Proteins c-akt/antagonists & inhibitors
- Proto-Oncogene Proteins c-akt/metabolism
- Proto-Oncogene Proteins c-bcl-2/biosynthesis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Signal Transduction/drug effects
- Terpenes/adverse effects
- Terpenes/pharmacology
- Terpenes/therapeutic use
Collapse
Affiliation(s)
- C Billard
- Centre de Recherche des Cordeliers UMRS 872, Paris cedex, France
| | | | | |
Collapse
|
19
|
|
20
|
Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta Rev Cancer 2011; 1825:29-36. [PMID: 22020293 DOI: 10.1016/j.bbcan.2011.10.001] [Citation(s) in RCA: 242] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 10/03/2011] [Accepted: 10/04/2011] [Indexed: 12/14/2022]
Abstract
This review focuses on matrix metalloproteinases (MMPs)-2 (gelatinase A) and -9 (gelatinase B), both of which are cancer-associated, secreted, zinc-dependent endopeptidases. Gelatinases cleave many different targets (extracellular matrix, cytokines, growth factors, chemokines and cytokine/growth factor receptors) that in turn regulate key signaling pathways in cell growth, migration, invasion, inflammation and angiogenesis. Interactions with cell surface integral membrane proteins (CD44, αVβ/αβ1/αβ2 integrins and Ku protein) can occur through the gelatinases' active site or hemopexin-like C-terminal domain. This review evaluates the recent literature on the non-enzymatic, signal transduction roles of surface-bound gelatinases and their subsequent effects on cell survival, migration and angiogenesis. Gelatinases have long been drug targets. The current status of gelatinase inhibitors as anticancer agents and their failure in the clinic is discussed in light of these new data on the gelatinases' roles as cell surface transducers - data that may lead to the design and development of novel, gelatinase-targeting inhibitors.
Collapse
Affiliation(s)
- Brigitte Bauvois
- INSERM U872, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris Descartes, Paris, France.
| |
Collapse
|
21
|
Merhi F, Tang R, Piedfer M, Mathieu J, Bombarda I, Zaher M, Kolb JP, Billard C, Bauvois B. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One 2011; 6:e25963. [PMID: 21998731 PMCID: PMC3188562 DOI: 10.1371/journal.pone.0025963] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 09/14/2011] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND The natural phloroglucinol hyperforin HF displays anti-inflammatory and anti-tumoral properties of potential pharmacological interest. Acute myeloid leukemia (AML) cells abnormally proliferate and escape apoptosis. Herein, the effects and mechanisms of purified HF on AML cell dysfunction were investigated in AML cell lines defining distinct AML subfamilies and primary AML cells cultured ex vivo. METHODOLOGY AND RESULTS HF inhibited in a time- and concentration-dependent manner the growth of AML cell lines (U937, OCI-AML3, NB4, HL-60) by inducing apoptosis as evidenced by accumulation of sub-G1 population, phosphatidylserine externalization and DNA fragmentation. HF also induced apoptosis in primary AML blasts, whereas normal blood cells were not affected. The apoptotic process in U937 cells was accompanied by downregulation of anti-apoptotic Bcl-2, upregulation of pro-apoptotic Noxa, mitochondrial membrane depolarization, activation of procaspases and cleavage of the caspase substrate PARP-1. The general caspase inhibitor Z-VAD-fmk and the caspase-9- and -3-specific inhibitors, but not caspase-8 inhibitor, significantly attenuated apoptosis. HF-mediated apoptosis was associated with dephosphorylation of active Akt1 (at Ser(473)) and Akt1 substrate Bad (at Ser(136)) which activates Bad pro-apoptotic function. HF supppressed the kinase activity of Akt1, and combined treatment with the allosteric Akt1 inhibitor Akt-I-VIII significantly enhanced apoptosis of U937 cells. SIGNIFICANCE Our data provide new evidence that HF's pro-apoptotic effect in AML cells involved inhibition of Akt1 signaling, mitochondria and Bcl-2 members dysfunctions, and activation of procaspases -9/-3. Combined interruption of mitochondrial and Akt1 pathways by HF may have implications for AML treatment.
Collapse
Affiliation(s)
- Faten Merhi
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| | - Ruoping Tang
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
- AP-HP, Département d'Hématologie, Hôpital St Antoine, Paris, France
| | - Marion Piedfer
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| | | | - Isabelle Bombarda
- ISM2-AD2M, UMR CNRS 6263, Université Paul Cézanne, Marseille, France
| | - Murhaf Zaher
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| | - Jean-Pierre Kolb
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| | - Christian Billard
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| | - Brigitte Bauvois
- INSERM U872, Université Pierre et Marie Curie, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
22
|
Zaher M, Tang R, Bombarda I, Merhi F, Bauvois B, Billard C. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. Int J Oncol 2011; 40:269-76. [PMID: 21947285 DOI: 10.3892/ijo.2011.1206] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 07/22/2011] [Indexed: 11/05/2022] Open
Abstract
We previously reported that hyperforin, a phloroglucinol purified from Hypericum perforatum, induces the mitochondrial pathway of caspase-dependent apoptosis in chronic lymphocytic leukemia (CLL) cells ex vivo, and that this effect is associated with upregulation of Noxa, a BH3-only protein of the Bcl-2 family. Here, we investigated the role of this upregulation in the pro-apoptotic activity of hyperforin in the cells of CLL patients and MEC-1 cell line. We found that the increase in Noxa expression is a time- and concentration-dependent effect of hyperforin occurring without change in Noxa mRNA levels. A post-translational regulation is suggested by the capacity of hyperforin to inhibit proteasome activity in CLL cells. Noxa silencing by siRNA reduces partially hyperforin-elicited apoptosis. Furthermore, treatment with hyperforin, which has no effect on the expression of the prosurvival protein Mcl-1, induces the interaction of Noxa with Mcl-1 and the dissociation of Mcl-1/Bak complex, revealing that upregulated Noxa displaces the proapoptotic protein Bak from Mcl-1. This effect is accompanied with Bak activation, known to allow the release of apoptogenic factors from mitochondria. Our data indicate that Noxa upregulation is one of the mechanisms by which hyperforin triggers CLL cell apoptosis. They also favor that new agents capable of mimicking specifically the BH3-only protein Noxa should be developed for apoptosis-based therapeutic strategy in CLL.
Collapse
Affiliation(s)
- Murhaf Zaher
- Centre de Recherche des Cordeliers, INSERM U872, Equipe 18, Paris, France
| | | | | | | | | | | |
Collapse
|
23
|
Merhi F, Auger J, Rendu F, Bauvois B. Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines. Biologics 2011; 2:885-95. [PMID: 19707466 PMCID: PMC2727902 DOI: 10.2147/btt.s3212] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Epidemiologic studies support the premise that Allium vegetables may lower the risk of cancers. The beneficial effects appear related to the organosulfur products generated upon processing of Allium. Leukemia cells from patients with acute myeloid leukemia (AML) display high proliferative capacity and have a reduced capacity of undergoing apoptosis and maturation. Whether the sulfur-containing molecules thiosulfinates (TS), diallyl TS (All(2)TS), dipropyl TS (Pr(2)TS) and dimethyl TS (Me(2)TS), are able to exert chemopreventative activity against AML is presently unknown. The present study was an evaluation of proliferation, cytotoxicity, differentiation and secretion of AML cell lines (U937, NB4, HL-60, MonoMac-6) in response to treatment with these TS and their related sulfides (diallylsulfide, diallyl disulfide, dipropyl disulfide, dimethyl disulfide). As assessed by flow cytometry, ELISA, gelatin zymogaphy and RT-PCR, we showed that Pr(2)TS and Me(2)TS, but not All(2)TS and sulfides, 1) inhibited cell proliferation in dose- and time-dependent manner and this process was neither due to cytotoxicity nor apoptosis, 2) induced macrophage maturation, and 3) inhibited the levels of secreted MMP-9 (protein and activity) and TNF-alpha protein, without altering mRNA levels. By establishing for the first time that Pr(2)TS and Me(2)TS affect proliferation, differentiation and secretion of leukemic cell lines, this study provides the opportunity to explore the potential efficiency of these molecules in AML.
Collapse
Affiliation(s)
- Faten Merhi
- UMR 7131 UPMC Paris Universitas/ CNRS, Groupe Hospitalier Broussais-HEGP, Paris, France
| | | | | | | |
Collapse
|
24
|
Abstract
The transmembrane metalloprotease aminopeptidase‐N (APN)/CD13 is overexpressed in various solid and hematological malignancies in humans, including acute myeloid leukemia (AML) and is thought to influence tumor progression. Here, we investigated the contribution of APN/CD13 to the regulation of growth and survival processes in AML cells in vitro. Anti‐CD13 monoclonal antibodies MY7 and SJ1D1 (which do not inhibit APN activity) and WM15 (an APN‐blocking antibody) inhibited the growth of the AML cell line U937 and induced apoptosis, as evidenced by cell accumulation in the sub‐G1 phase, DNA fragmentation, and phosphatidylserine externalization. Isotype‐matched IgG1 and the APN/CD13 enzymatic inhibitors bestatin and 2' ,3‐dinitroflavone‐8‐acetic acid, were ineffective. Internalization of CD13‐MY7 complex into cells was followed by mitochondrial membrane depolarization, Bcl‐2 and Mcl‐1 down‐regulation, Bax up‐regulation, caspase‐9, caspase‐8, and caspase‐3 activation, and cleavage of the caspase substrate PARP‐1. The broad‐spectrum caspase inhibitor Z‐VAD‐fmk and the caspase‐9‐ and caspase‐8‐specific inhibitors significantly attenuated apoptosis. CD13 ligation also induced apoptosis and PARP‐1 cleavage in primary AML blasts, whereas normal blood cells were not affected. Overall, these data provide new evidence that CD13 can serve as a target for inducing caspase‐dependent apoptosis in AML (independently of its APN activity). These findings may have implications for tumor biology and treatment.—Piedfer, M., Dauzonne, D., Tang, R., N'Guyen, J., Billard, C., Bauvois, B. Aminopeptidase‐N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 25, 2831‐2842 (2011). http://www.fasebj.org
Collapse
Affiliation(s)
- Marion Piedfer
- Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale (INSERM) U872, Paris, France
| | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- B Bauvois
- U365 INSERM, Institut Curie, Paris, France
| | - A Laouar
- U365 INSERM, Institut Curie, Paris, France
| |
Collapse
|
26
|
Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF- 1 in patients with distinct types of primary glomerulonephritis. Nephrol Dial Transplant 2007; 22:1115-22. [PMID: 17205957 DOI: 10.1093/ndt/gfl743] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Dysregulated renal expression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMP) and TGF-beta1 contribute to the development of tubulo-interstitial fibrosis characteristic of progressive forms of primary glomerulonephritis (GN). There is little information on the circulating levels of these proteins in human GNs. Here, we assessed whether different histopathological GN types could be associated with distinct plasma patterns of MMPs and regulatory proteins. METHODS Protein levels of MMP-2, MMP-9, TGF-beta1 and TIMP-1 were measured by ELISA in plasma from venous blood of 108 untreated patients with various types of primary GN defined by kidney biopsy, namely IgAN (n=63), membranous GN (MN, n=26), minimal change nephrotic syndrome (MCNS, n=12) and focal and segmental glomerular sclerosis (FSGS, n=7), and were compared with levels in 50 healthy subjects. Plasma samples were assayed for gelatinolytic activity (zymography). RESULTS Zymography detected the proforms of MMP-2 and MMP-9. Compared with controls, IgAN patients exhibited a significant, parallel decrease in plasma levels of MMP-2, MMP-9 and TGF-beta1. In MN patients, decreased MMP-9 level contrasted with a high MMP-2 level and a normal TGF-beta1 level. In the MCNS/FSGS group, increased MMP-2 level contrasted with unchanged MMP-9 and decreased TGF-beta1 levels. Plasma concentration of TIMP-1 was elevated in all GN groups. There was no correlation between baseline MMP-2/MMP-9/TIMP-1/TGF-beta1 levels and the degree of renal dysfunction or with progression toward ESRD. CONCLUSIONS Plasma concentrations of MMP-2, MMP-9 and TGF-beta1 significantly differed between the various histopathological types of primary GNs, thus suggesting the involvement of different underlying mechanisms in the regulation of glomerular and tubulointerstitial fibrosis in these renal diseases.
Collapse
|
27
|
Affiliation(s)
| | - Brigitte Bauvois
- CNRS UMR 7131, Hopital Broussais-HEGP, 102 rue Didot, 75014 Paris, France
| |
Collapse
|
28
|
Obeid D, Nguyen J, Lesavre P, Bauvois B. Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells. Oncogene 2006; 26:102-10. [PMID: 16799629 DOI: 10.1038/sj.onc.1209779] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The transmembrane metalloproteases angiotensin-converting enzyme (ACE) and tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE/ADAM-17) have been associated with inflammation, cancer progression and angiogenesis. Few investigations into the regulation of these enzymes by physiological stimuli have been reported. In this study, we investigated the influence of interferons (IFNs) type I (alpha, beta) and II (gamma) on ACE and TACE expression of human leukemic NB4 cells and monocytes. We assessed the expression of proteases by reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay and immunofluorescence analyses. IFNgamma, but not type I IFNs, upregulated membrane ACE in a dose- and time-dependency and this was reflected by the increase of ACE enzymatic activity and ACE mRNA. ACE upregulation was dependent on protein synthesis. Treatment of the interferon responsive factor 1 (IRF1)-unresponsive HepG2 cell line with IFNgamma did not affect ACE expression, thus suggesting the participation of the IRF1 signaling pathway in IFNgamma-mediated ACE upregulation in myeloid cells. In contrast, both types of IFNs, in a dose- and time-dependent manner, downregulated surface TACE without affecting TACE transcript. Soluble TACE was not detected in the medium of IFN-treated cells. IFNgamma-mediated decrease of surface TACE in NB4 cells was reversible, and correlated with an increase in intracellular TACE, suggesting that cell surface TACE was internalized in response to IFNs. These findings, showing the presence of IFN-dependent controlled mechanisms by which ACE and TACE levels are regulated in human normal and leukemic myeloid cells, may have implications in the context of current investigations on the therapeutic potential of IFNs.
Collapse
Affiliation(s)
- D Obeid
- INSERM 507, Hôpital Necker, Bâtiment Lavoisier, Paris, France
| | | | | | | |
Collapse
|
29
|
Nguyen J, Dumont J, Bauvois B. Comparative effects of interferon-gamma and all- trans retinoic acid on secreted and surface-associated matrix metalloproteinase-9 expression of human monocytes. Cell Mol Biol (Noisy-le-grand) 2006; 52:51-8. [PMID: 16914095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2005] [Accepted: 11/17/2005] [Indexed: 05/11/2023]
Abstract
Matrix metalloproteinase-9 is involved in inflammation and tumor progression. We previously demonstrated that interferon type I (alpha/beta) and II (gamma) inhibit matrix metalloproteinase-9 (92kDa) gene expression on lymphocytes from patients with B chronic lymphocytic leukemia and human monocytes. Since all-trans retinoic acid (ATRA) can regulate some interferon -responsive genes, we studied here the effects of all-trans retinoic acid onto matrix metalloproteinase-9 levels in these cells. By using RT-PCR, ELISA and zymography experiments, we showed that all-trans retinoic acid down-regulated matrix metalloproteinase-9 synthesis (mRNA,protein) and secretion. The inhibitory action of all-trans retinoic acid toward matrix metalloproteinase-9 was however not associated with the STAT1/IRF-1 pathway involved in interferon-mediated matrix metalloproteinase-9 inhibition indicating that all-trans retinoic acid did not bypass IFN receptor signaling. Using flow cytometry, we detected on the surface of monocytes low expression of matrix metalloproteinase-9 and Fc-gammaRI, and high expression of HLA-DR, beta1 and beta2 integrins. Enhancement of Fc-gammaRI and HLA-DR on monocytes by interferon-gamma, but not by all-trans retinoic acid, was accompanied by up-regulation of surface matrix metalloproteinase-9. Furthermore, we showed that all-trans retinoic acid down-regulated matrix metalloproteinase-9 expression in lymphocytes of untreated patients with early stage B chronic lymphocytic leukemia. Together, our data suggest the potential relevance of all-trans retinoic acid as a pharmacological tool to attenuate matrix metalloproteinase-9 secretion in pathological situations.
Collapse
Affiliation(s)
- J Nguyen
- INSERM 507, Hôpital Necker Bâtiment Lavoisier 161 rue de Sèvres, 75015 Paris, France
| | | | | |
Collapse
|
30
|
Nguyen J, Gogusev J, Knapnougel P, Bauvois B. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol Lett 2006; 106:34-41. [PMID: 16720051 DOI: 10.1016/j.imlet.2006.04.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2006] [Revised: 04/03/2006] [Accepted: 04/09/2006] [Indexed: 11/27/2022]
Abstract
Matrix metalloproteinase-9 (MMP-9), through its catalytic and non-catalytic activities, plays critical roles in inflammation, tumor invasion and angiogenesis. Human monocytes actively involved in inflammatory and tumoral states secrete proMMP-9 (92kDa). Endogenous TNF-alpha stimulates MMP-9 gene transcription in monocytes through NF-kappaB activation. In this study, we investigated the intracellular signaling pathways underlying TNF-alpha/NF-kappaB-dependent expression of MMP-9 in monocytes using chemical inhibitors that specifically inhibit distinct kinase pathways. We confirmed the expression of MMP-9 by reverse transcription chain reaction (RT-PCR), ELISA and gelatin zymography. PGE2/cAMP inhibitor indomethacin, PI-3K inhibitor wortmannin, PKC inhibitor bisindolylmaleimide and PKA inhibitor H-89 did not affect the levels of released MMP-9. In contrast, MMP-9 mRNA and protein expression was down-regulated by p38 MAPK inhibitor SB203580 and protein tyrosine kinase (PTK) inhibitor tyrphostin 25. These inhibitors increased IkappaB-alpha levels, which correlate with decreased NF-kappaB activation. Although SB203580 induced a decrease in TNF-alpha release, addition of exogenous TNF-alpha did not reverse the inhibitory effect of SB203580 toward MMP-9 thus suggesting that SB203580 could modulate down-stream effects of TNF-alpha. In parallel, TIMP-1 levels decreased in the presence of SB203580. Both kinase inhibitors did not influence the maturation pathway of monocytes. Our results indicate that these two inhibitors of p38 MAPK and PTK pathways could be used as combined targets for inhibiting MMP-9 expression in inflamed tissues.
Collapse
|
31
|
Abstract
Aminopeptidase N (APN)/CD13 (EC 3.4.11.2) is a transmembrane protease present in a wide variety of human tissues and cell types (endothelial, epithelial, fibroblast, leukocyte). APN/CD13 expression is dysregulated in inflammatory diseases and in cancers (solid and hematologic tumors). APN/CD13 serves as a receptor for coronaviruses. Natural and synthetic inhibitors of APN activity have been characterized. These inhibitors have revealed that APN is able to modulate bioactive peptide responses (pain management, vasopressin release) and to influence immune functions and major biological events (cell proliferation, secretion, invasion, angiogenesis). Therefore, inhibition of APN/CD13 may lead to the development of anti-cancer and anti-inflammatory drugs. This review provides an update on the biological and pharmacological profiles of known natural and synthetic APN inhibitors. Current status on their potential use as therapeutic agents is discussed with regard to toxicity and specificity.
Collapse
Affiliation(s)
- Brigitte Bauvois
- Unité INSERM 507, Hôpital Necker, Université René Descartes Paris V, Bâtiment Lavoisier, 161 rue de Sèvres, 75015 Paris, France
| | - Daniel Dauzonne
- UMR 176 Institut Curie‐CNRS, Institut Curie, Section Recherche, 26 rue d'Ulm, 75248 Paris CEDEX 05, France
| |
Collapse
|
32
|
Nguyen J, Knapnougel P, Lesavre P, Bauvois B. Inhibition of matrix metalloproteinase-9 by interferons and TGF-β1 through distinct signalings accounts for reduced monocyte invasiveness. FEBS Lett 2005; 579:5487-93. [PMID: 16213498 DOI: 10.1016/j.febslet.2005.09.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2005] [Revised: 09/08/2005] [Accepted: 09/10/2005] [Indexed: 01/17/2023]
Abstract
Cytokines may provide signals for regulating human monocyte matrix metalloproteinase-9 (MMP-9) activity. In this study, we investigated the roles of interferons (IFN) type I/II and transforming growth factor-beta1 (TGF-beta1) in MMP-9-mediated invasiveness. MMP-9 antibody and inhibitor, IFNs and TGF-beta1 inhibited monocyte transmigration through Matrigel. IFNs and TGF-beta1 downregulated MMP-9 mRNA, protein and activity levels. The inhibitory action of IFNs was associated with the STAT1/IRF-1 pathway since the JAK inhibitor AG490 blocked STAT1 phosphorylation, IRF-1 synthesis and counteracted the blockade of MMP-9 release. TGF-beta1-mediated MMP-9 inhibition appeared STAT1/IRF-1-independent but reversed by the protein tyrosine kinase inhibitor tyrphostin 25. Our data point out the importance of IFNs and TGF-beta1 in the control of monocyte MMP-9-mediated extravasation.
Collapse
Affiliation(s)
- Juliette Nguyen
- INSERM 507, Hôpital Necker, Bâtiment Lavoisier, Paris, France
| | | | | | | |
Collapse
|
33
|
Abstract
Transmembrane proteases (TPs) are proteins anchored in the plasma membrane with their catalytic site exposed to the external surface of the membrane. TPs are widely expressed, and their dysregulated expression is associated with cancer, infection, inflammation, autoimmune and cardiovascular diseases, all diseases where angiogenesis is part of the pathology. TPs participate in extracellular proteolysis (degradation of extracellular matrix components, regulation of chemokine activity, release of membrane-anchored cytokines, cytokine receptors and adhesion molecules) and influence cell functions (growth, secretion of angiogenic molecules, motility). Recent attention has been focused on the ADAM-17 (a disintegrin and metalloprotease)/TACE/CD156q, the MT1-MMP (membrane-type-1 matrix metallo proteinase)/MMP-14, and the ectopeptidases aminopeptidase N (APN/CD13), dipeptidyl peptidase IV (DPPIV/CD26) and angiotensin-converting enzyme (ACE/CD143), that appear to have a critical role in angiogenesis. This article summarizes current knowledge on these TPs, and reviews recent investigations that document their participation during angiogenic-related events. Through their multiple roles, TPs may thereby provide critical links in angiogenesis.
Collapse
Affiliation(s)
- Brigitte Bauvois
- Brigitte Bauvois, Unité 507 INSERM, Hôpital Necker, Bâtiment Lavoisier, 161 rue de Sèvres, 75015 Paris, France.
| |
Collapse
|
34
|
Sancéau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003; 278:36537-46. [PMID: 12847101 DOI: 10.1074/jbc.m304300200] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Enhanced expression of (pro)matrix metalloproteinase-9 (MMP-9) is associated with human tumor invasion and/or metastasis. COH cells derived from a highly invasive and metastatic Ewing's sarcoma constitutively express proMMP-9. Transfection of a double stranded RNA that targets the MMP-9 mRNA into COH cells depleted the corresponding mRNA and protein as demonstrated by reverse transcriptase-PCR, enzyme-linked immunosorbent assay, and gelatin zymography. proMMP-9 extinction resulted in the following: (i) decreased spreading on extracellular matrix (fibronectin, laminin, collagen IV)-coated surfaces, (ii) inhibition of migration toward fibronectin, and (iii) induced aggregation, which was specifically disrupted by a function-blocking E-cadherin antibody. MMP-9 knockdown concomitantly resulted in increased levels of surface E-cadherin, redistribution at the plasma membrane of beta-catenin, and its physical association with E-cadherin. Moreover, induction of E-cadherin-mediated adhesion was associated with RhoA activation and changes in paxillin cytoskeleton. Finally, an inhibitor of gelatinolytic activity of pro-MMP9 did not reduce COH cell migration confirming that the enzymatic property of COH MMP-9 was not required for migration toward fibronectin. Overall, our observations define a novel critical role for proMMP-9 in providing a cellular switch between stationary and migratory cell phases.
Collapse
Affiliation(s)
- Josiane Sancéau
- Unité 365 INSERM, Institut Curie, 75248 Paris cedex 05, France
| | | | | |
Collapse
|
35
|
Bauvois B, Puiffe ML, Bongui JB, Paillat S, Monneret C, Dauzonne D. Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13. J Med Chem 2003; 46:3900-13. [PMID: 12930151 DOI: 10.1021/jm021109f] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The cell surface aminopeptidase N (APN/CD13), overexpressed in tumor cells, plays a critical role in angiogenesis. However, potent, selective, and, particularly, noncytotoxic inhibitors ot this protein are lacking, and the present work was undertaken with the aim of developing a new generation of noncytotoxic inhibitors that bind to APN/CD13. In this context, we have synthesized a series of novel flavone-8-acetic acid derivatives. Among the herein described and evaluated compounds, the 2',3-dinitroflavone-8-acetic acid (19b) proved to be the most efficient and exhibited an IC(50) of 25 microM which is 2.5 times higher than that of bestatin (1), the natural known inhibitor of APN/CD13. However, in contrast to bestatin (1), the dinitroflavone 19b did not induce any cytotoxicity to cultured human model cells. The presence of other substituents such as NO(2) or OCH(3) groups at the 3'- or 4'-position of the B phenyl group, or the existence of steric constraints (compounds 24 and 29), did not improve selectivity and potency. The flavone 19b affinity for APN/CD13 is not recovered with other proteases such as matrix metalloproteinase-9 (MMP-9), angiotensin converting enzyme (ACE/CD143), neutral endopeptidase (NEP/CD10), gamma-glutamyl transpeptidase (CD224), or the serine proteases dipeptidyl peptidase IV (DPPIV/CD26) or cathepsin G.
Collapse
Affiliation(s)
- Brigitte Bauvois
- Unité 365 INSERM, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | |
Collapse
|
36
|
Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 2003; 27:59-68. [PMID: 12727530 DOI: 10.1016/s1386-6532(02)00128-2] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Dipeptidyl peptidase IV is a transmembrane enzyme widely expressed in many cell types, but also present as a soluble form in biological fluids. Its abnormal activity is sometimes associated with liver disease related pathologies. OBJECTIVES The aim of this study was to evaluate the clinical relevance of changes in serum DPPIV activity in hepatitis C and other viral infections. STUDY DESIGN DPPIV activity was assessed by using a microplate-based colorimetric assay on serum from 88 subjects: 12 healthy uninfected controls, 10 patients with primary biliary cirrhosis (PBC) as a reference group, 36 HCV-infected patients, and patients suffering from viral infections of different etiologies. Levels of DPPIV activity were compared with: (1) those of other serum biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT), and bilirubin concentrations; and (2) criteria representative of liver histological status. RESULTS Compared with healthy subjects, DPPIV activity was significantly increased during viral infections and in PBC (P<0.01). In HCV-infected patients, the median activity (interquartile range, IQR), 29.78 IU/l (24.66-35.95), differed significantly (P<0.05) from that of controls: 21.42 (19.76-24.93). No correlation was observed between DPPIV activity and either ALT, AST, bilirubin, or the stage of liver fibrosis and necroinflammatory activity, although GGT was moderately correlated (r=0.58, P<0.05). CONCLUSIONS Although we confirmed an elevation of serum DPPIV activity in PBC, it seems to be a non-specific phenomenon common to viral infections. The absence of correlation between serum DPPIV and markers of liver disease in HCV-infected patients, suggests that this activity originates not only from the liver, but also from other sources such as peripheral blood cells involved in the control of viral infections.
Collapse
Affiliation(s)
- T Andrieu
- Laboratoire de Virologie, CERVI, UPRES EA 2387, Groupe Hospitalier Pitié-Salpêtrière, 75651 Paris Cedex 13, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Senten K, Van der Veken P, Bal G, De Meester I, Lambeir AM, Scharpé S, Bauvois B, Haemers A, Augustyns K. Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett 2002; 12:2825-8. [PMID: 12270155 DOI: 10.1016/s0960-894x(02)00603-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Structure-activity investigations of product-like dipeptide analogues lacking the C-terminal carbonyl function resulted in potent and selective dipeptidyl peptidase II (DPP II) inhibitors. Dab-Pip has an IC(50)=0.13 microM for DPP II and a 7600-fold selectivity with respect to DPP IV. This compound will be highly valuable for the investigation of the biochemical function of DPP II.
Collapse
Affiliation(s)
- Kristel Senten
- Department of Medicinal Chemistry, University of Antwerp (UIA), Universiteitsplein 1, Antwerpen, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Sancéau J, Boyd DD, Seiki M, Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 2002; 277:35766-75. [PMID: 12105194 DOI: 10.1074/jbc.m202959200] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Enhanced expression of matrix metalloproteinase-9 (MMP-9) correlates with invasion during tumor progression. Interferons (IFNs) inhibit MMP-9 activation in response to tumor necrosis factor-alpha (TNF-alpha), and the latter activates the MMP-9 gene through NF-kappaB. Understanding the molecular basis for MMP-9 inhibition may provide tools to control cell invasion. The data reported here show the critical role of interferon regulatory factor-1 (IRF1) in the inhibition of MMP-9. (i) IFN treatment suppresses TNF-alpha-induced MMP-9 reporter activity in STAT1(+/+) cells but not in STAT1(-/-) cells. (ii) IRF1 transfection blocks TNF-alpha-mediated MMP-9 activation. (iii) IFNs phosphorylate STAT1 and induce IRF1 but do not affect Ikappa-B degradation nor NF-kappaB nuclear translocation. (iv) Nuclear NF-kappaB (p50/p65) and IRF1, but not STAT1, bind to the MMP-9 promoter region containing an IFN-responsive-like element overlapping the NF-kappaB-binding site. (v) Recombinant IRF1, although unable to bind to an NF-kappaB consensus sequence, competes with NF-kappaB proteins for binding to the MMP-9 promoter. (vi) Conversely recombinant p50/p65 proteins reduce IRF1-DNA binding. (vii) In cells cotransfected with IRF1 and/or p65 expression vectors, an excess of IRF1 reduces MMP-9 reporter activity, whereas an excess of p65 blocks the inhibitory effect of IFN-gamma. Thus, in contrast to the known synergism between IRF1 and NF-kappaB, our data identify a novel role for IRF1 as a competitive inhibitor of NF-kappaB binding to the particular MMP-9 promoter context.
Collapse
Affiliation(s)
- Josiane Sancéau
- Unité 365 INSERM, Section de Recherche, Institut Curie, 75248 Paris Cedex 05, France
| | | | | | | |
Collapse
|
39
|
Surin B, Rouillard D, Bauvois B. Interactions between human monocytes and fibronectin are suppressed by interferons β and γ, but not α: Correlation with Rho-paxillin signaling. Int J Mol Med 2002. [DOI: 10.3892/ijmm.10.1.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
40
|
Surin B, Rouillard D, Bauvois B. Interactions between human monocytes and fibronectin are suppressed by interferons beta and gamma, but not alpha: correlation with Rho-paxillin signaling. Int J Mol Med 2002; 10:25-31. [PMID: 12060847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Modulation of the adhesive responses of monocytic cells may reflect their motility at sites of diseased tissues (inflammation, tumors). Integrins alpha5beta1 mediate fibronectin (Fn)-dependent adhesion of human monocytes and their precursors. The effect of type I IFNs (alpha, beta) and type II IFN (gamma) was assessed on the adhesive capacities of promonocytic U937 cells and monocytes. IFN-beta and IFN-gamma abrogated monocytic cell adhesion to Fn, but such impaired cell attachment was not due to altered levels of alpha5beta1 integrins. In contrast, IFN-alpha did not affect cell adhesion to Fn. Participation of cytoskeleton assembly in IFN-mediated cell detachment was evaluated. Activation of RhoA activity with lysophosphatidic acid (LPA) increased 2-fold the adhesion of monocytic cells to Fn in a alpha5beta1-mediated fashion, and IFN-gamma treatment reversed the enhancing effect of LPA. Moreover, U937 cells and monocytes dominantly expressed the 44-46 kDa paxillin forms and IFN-beta and IFN-gamma led to the accumulation of 66-70 kDa paxillin forms. These results indicate that IFN-mediated loss of monocyte adhesion to Fn is associated with changes in the cytoskeleton associated proteins paxillin and Rho.
Collapse
Affiliation(s)
- Brigitte Surin
- Unite 365 INSERM, Institut Curie, 75231 Paris cedex 05, France
| | | | | |
Collapse
|
41
|
Abstract
The genetic hallmark of Ewing's sarcoma family of tumours (ET) is the presence of the translocation t(11;22)(q24;q12), which creates the ET fusion gene, leading to cellular transformation. Five human gamma-glutamyl transpeptidase (gamma-GT) genes are located near the chromosomal translocation in ET. gamma-GT is a major enzyme involved in glutathione homoeostasis. Five human cell lines representative of primary or metastatic tumours were investigated to study whether gamma-GT alterations could occur at the chromosomal breaks and rearrangements in ET. As shown by enzymic assays and FACS analyses, all ET cell lines consistently expressed a functional gamma-GT which however did not discriminate steps of ET progression. As shown previously [Sancéau, Hiscott, Delattre and Wietzerbin (2000) Oncogene 19, 3372-3383], ET cells respond to the antiproliferative effects of interferons (IFNs) type I (alpha and beta) and to a much less degree to IFN type II (gamma). IFN-alpha and -beta arrested cells in the S-phase of the cell cycle. We found an enhancement of gamma-GT mRNA species with IFN-alpha and -beta by reverse transcriptase-PCR analyses. This is reflected by up-regulation of gamma-GT protein, which coincides with the increase in gamma-GT-specific enzymic activity. Similarly, IFNs up-regulate the levels of gamma-GT in another IFN-responsive B cell line. Whether this up-regulation of gamma-GT by IFNs is of physiological relevance to cell behaviour remains to be studied.
Collapse
Affiliation(s)
- Lena Bouman
- Unité 365 INSERM, Section de Recherche, Institut Curie, 75248 Paris Cedex 05, France
| | | | | | | |
Collapse
|
42
|
Surin B, Rouillard D, Bauvois B. Loss of alpha5beta1-mediated adhesion of monocytic cells to fibronectin by interferons beta and gamma is associated with changes in actin and paxillin cytoskeleton. Hematol J 2002; 1:172-80. [PMID: 11920186 DOI: 10.1038/sj.thj.6200027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/1999] [Accepted: 02/15/2000] [Indexed: 11/09/2022]
Abstract
INTRODUCTION Modulation of the adhesive responses of monocytic cells may reflect their motility within the bone marrow and at sites of inflammation. Monocyte alpha5beta1 integrins mediate fibronectin-dependent adhesion. We previously showed that type II IFN-gamma reduces adhesiveness to fibronectin (Fn) whereas TGF-beta1 enhances cell attachment. Here, we investigate the role of type I IFNs (alpha, beta) on the adhesive capacity of monocytic cells. MATERIALS AND METHODS The influence of IFNs on the human U937 cell line adhesion to fibronectin-coated surfaces was determined. The expression of integrins and cytoskeleton proteins was analyzed by FACS, Western blotting and/or fluorescence microscopy analyses. RESULTS IFN-alpha did not affect cell adhesion to fibronectin. In contrast, IFN-beta, like IFN-gamma, abrogated U937 adhesion to fibronectin and antagonized TGF-beta1-mediated cell attachment to Fn. The impaired binding of IFN-beta- and IFN-gamma-treated cells to fibronectin was not due to reduced levels of alpha5beta1 integrins. IFN-beta and IFN-gamma re-organized filamentous actin, and such rearrangement differed from that observed in TGF-beta1-adhesive cells. U937 cells dominantly expressed 44 to 46 kDa paxillin forms and treatment with IFNs enhanced the number of 66 to 70 kDa forms of paxillin. CONCLUSION Our data show that IFN-beta and IFN-gamma induced loss of monocytic adhesion to fibronectin associated with changes in actin and paxillin cytoskeleton, thereby pointing to a possible effect of these cytokines in monocyte trafficking.
Collapse
Affiliation(s)
- B Surin
- Unité 365 INSERM, Institut Curie, 75231 Paris cedex 05, France
| | | | | |
Collapse
|
43
|
Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002; 16:791-8. [PMID: 11986939 DOI: 10.1038/sj.leu.2402472] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2001] [Accepted: 01/14/2002] [Indexed: 11/09/2022]
Abstract
Besides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs) play critical roles in angiogenesis, tumor invasion and metastasis. Increased angiogenesis is observed in chronic B lymphocytic leukemia (B-CLL) and published data reported VEGF and bFGF production in this disease. The purpose of this study was to investigate MMP expression in early stage B-CLL. Elevated MMP-9 concentrations were detected by ELISA in the sera of B-CLL patients (median level 250 ng/ml) compared with healthy donors (67 ng/ml) (P < 0.0001), and immunostaining with antibodies against MMP-9 and B cell antigens (CD19, CD23) substantiated the presence of MMP-9 in tumoral B lymphocytes. By using RT-PCR, ELISA and zymography experiments, we confirmed that B-CLL cells expressed and released the pro-form of MMP-9 with Mr 92 kDa (158-1300 pg/ml/10(6) cells/48 h), p-aminophenylmercuric acetate generating a 82 kDa active form. In contrast, the production of MMP-9 by normal counterpart B cells was significantly low (28-169 pg/ml/10(6)cells/48 h). Moreover, B-CLL culture supernatants contained bFGF (median levels 17 pg/ml/10(6) cells/48 h), VEGF (1.4 pg/ml/10(6) cells/48 h) and TNF-alpha (0.2 pg/ml/10(6) cells/48 h). TNF-alpha and VEGF antibodies blocked MMP-9 at the mRNA and protein levels. Interferons (IFNs) type I or type II repressed MMP-9 gelatinolytic activity in a dose and time dependency, and this was reflected by a parallel inhibition of MMP-9 mRNA and protein. IFNs however did not affect the production of bFGF, VEGF and TNF-alpha. Together, our data show that B-CLL lymphocytes synthesize MMP-9 and emphasize the specific inhibitory actions of IFNs on its expression.
Collapse
Affiliation(s)
- B Bauvois
- Unité 365 INSERM, Section de Recherche, Institut Curie, Pavillon Pasteur, 26 rue d'Ulm, 75248 Paris cedex 05, France
| | | | | | | |
Collapse
|
44
|
Abstract
The inhibitor of gamma-glutamyl transpeptidase (gamma-GT) acivicin modulates cellular responses including growth, myeloid maturation and apoptosis. Whether these effects result from the inhibition of gamma-GT enzyme activity remains unclear. We compared the cellular effects of acivicin against a more potent and specific inhibitor of gamma-GT (L-2-amino-4-boronobutanoic acid (L-ABBA)) in gamma-GT-negative (B lymphoblastoid Ramos) and gamma-GT-positive (myelomonocytic HL-60, gamma-GT-transfected Ramos) cell lines. Under non-oxidative stress conditions, acivicin-induced cell growth arrest, apoptosis and macrophage maturation occurred independent of gamma-GT while L-ABBA did not influence any of these processes. Acivicin triggered tyrosine phosphorylation and increased nuclear factor kappaB activity. Further insight into the role of gamma-GT in cellular processes is needed.
Collapse
Affiliation(s)
- C Antczak
- Institut Curie, Section de Recherche, INSERM U365, Paris, France
| | | | | | | |
Collapse
|
45
|
Abstract
Acivicin is an antitumor agent known to inhibit cell growth. A new prodrug 9b of acivicin 10 was synthesized, based on a p-hydroxybenzylcarbamate self-immolative spacer capable to release acivicin under esterase activity. The prodrug includes a maleimide-containing arm for linkage with thiol-containing macromolecules such as antibodies. This molecule is intended for the conception of bioconjugates to target an inactive acivicin precursor to tumor cells, when linked to a monoclonal antibody (mAb) which recognizes a tumor-specific antigen. Prodrug cleavage by plasmatic esterases will then restore the acivicin's activity toward tumor cells. We report here the synthesis and the in vitro characteristics of the prodrug. As expected, its inhibitory activity against the gamma-glutamyl transpeptidase (gamma-GT) enzyme and its cytotoxicity towards HL-60 cells were highly reduced compared to the parent drug. The chemical and plasmatic hydrolysis kinetics of the compound was studied by HPLC. The prodrug is stable, being slowly hydrolyzed in pH 7.6 buffer at 37 degrees C with a half-life of 37 h. It is converted into an active acivicin under the effect of pig liver esterase, and its half-life in human plasma is 3 h. These results indicate this compound may be further used as a prodrug-antibody conjugate, to target acivicin to malignant cells.
Collapse
Affiliation(s)
- C Antczak
- Conception, synthèse et vectorisation de biomolécules, CNRS, UMR 176, Institut Curie-Section de Recherche, 26 rue d'Ulm, 75248 cedex 05, Paris, France
| | | | | | | |
Collapse
|
46
|
Abstract
The ectopeptidase gamma-glutamyltranspeptidase (gamma-GT) is overexpressed in myeloid leukemias. Its specific inhibitor, acivicin, was previously shown to induce an inhibitory growth effect associated with an induction of morphological features characteristic of macrophage maturation. We have considered a construction in which an antibody linked to a prodrug of acivicin will target acivicin to tumoral cells. In a first set of experiments we have synthesized a chromogenic model of this prodrug to validate this concept of prodrug, allowing an amine function to be released upon esterase action. Thereafter this model was applied to acivicin. The acivicin prodrug is inactive toward purified gamma-GT, and recovers its inhibitory activity under the effect of esterase.
Collapse
Affiliation(s)
- C Antczak
- Institut Curie-Section de Recherche, CNRS, UMR 176, 26 rue d'Ulm, 75248 cedex 05, Paris, France
| | | | | | | |
Collapse
|
47
|
Bauvois B. Transmembrane proteases in focus: diversity and redundancy? J Leukoc Biol 2001; 70:11-7. [PMID: 11435480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
Recent advances have led to the identification and characterization of an array of transmembrane proteases that mediate the proteolysis of various substrates (including bioactive peptides, components of the extracellular matrix, and integral proteins) and cell-cell or cell-matrix adhesion. The membrane proteases known to participate in these processes currently include the ectopeptidases, the membrane-type matrix metalloproteases (MT-MMPs), the ADAM (a disintegrin and metalloprotease) family, the meprins, and the secretases, and this list may be expected to grow. The roles that these molecules play within neoplastic and inflammatory sites are being investigated actively. The capacity of these ectoenzymes to transmit intracellular-transduction signals through the plasma membrane has to be considered. An appreciation of their functional redundancy is emerging.
Collapse
Affiliation(s)
- B Bauvois
- Unité 365 INSERM, Institut Curie, Paris, France.
| |
Collapse
|
48
|
|
49
|
Antczak C, De Meester I, Bauvois B. Transmembrane proteases as disease markers and targets for therapy. J BIOL REG HOMEOS AG 2001; 15:130-9. [PMID: 11501970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Transmembrane proteases (i.e. membrane-associated proteases, ectoproteases) are present in a wide variety of tissues and cell types including endothelial, epithelial and hematopoietic cells. Natural and synthetic inhibitors have been characterized and have revealed that certain ectoenzymes are able to modulate bioactive peptide responses and to influence major biological events such as cell proliferation, survival and invasiveness. Dysregulated expression of some of them in human diseases triggers research on their role in pathophysiology, on their value as disease markers and as putative targets for therapy.
Collapse
Affiliation(s)
- C Antczak
- Unité 365 Inserm, Institut Curie, Paris, France
| | | | | |
Collapse
|
50
|
Abstract
Ectopeptidases are transmembrane proteins present in a wide variety of tissues and cell types. Dysregulated expression of certain ectopeptidases in human malignancies suggests their value as clinical markers. Ectopeptidase interaction with agonistic antibodies or their inhibitors has revealed that these ectoenzymes are able to modulate bioactive peptide responses and to influence growth, apoptosis and differentiation, as well as adhesion and motility, all functions involved in normal and tumoral processes. There is evidence that ectopeptidase-mediated signal transduction frequently involves tyrosine phosphorylation. Combined analyses of gene organization and regulation of ectopeptidases by various physiological factors have provided insights into their structure-function relationships. Understanding the roles of ectopeptidases in pathophysiology may have implications in considering them as therapeutic targets.
Collapse
Affiliation(s)
- Christophe Antczak
- Institut Curie, INSERM 365, Paris, France.,Institute Curie, CNRS UMR 176, Paris, France
| | - Ingrid De Meester
- Institut Curie, INSERM 365, Paris, France.,Department of Pharmaceutical Sciences, University of Antwerp, Belgium
| | | |
Collapse
|